Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Study Type: Treatment
Phase: I/II
NCTID: NCT06287775
Principal Investigator:
Chao Huang
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection or Placebo in Combination with Chemotherapy Carboplatin/Cisplatin-Etoposide and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer LS-SCLC
A Phase I, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma Pro00039777
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy with Enzalutamide in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
An Open-Label Expanded Access Program Of Futibatinib TAS-120 In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Study Type: Treatment
Phase: II
NCTID: NCT04507503
Principal Investigator:
Ravi Chuda
Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Phase I/IB Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory AML or High-Grade MDS
Phase IIA Trial of Acolbifene 20 mg vs Low Dose Tamoxifen 5 mg in Pre-menopausal Women at High Risk for Development of Breast Cancer
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Randomized Phase II Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation
Study Type: Supportive Care
Phase: II
NCTID: NCT03667599
Principal Investigator:
Anthony Sung